Sugi Predict

Sugi Predict / Compounds / SCHEMBL17420448

SCHEMBL17420448

SCHEMBL17420448

CC(C)Oc1ccc(C(F)(F)C(=O)O)cc1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KMT2A Q03164 2/20 0.55
▸ PTPN5 P54829 2/20 0.54
▸ PARP10 Q53GL7 1/20 0.49
▸ ALDH1A1 P00352 4/20 0.47
▸ POLB P06746 1/20 0.46
▸ GRB2 P62993 1/20 0.45
▸ GLA P06280 1/20 0.45
▸ NR1H4 Q96RI1 1/20 0.44
▸ CYP3A4 P08684 1/20 0.43
▸ CYP3A5 P20815 1/20 0.43
▸ LMNA P02545 2/20 0.43
▸ TP53 P04637 2/20 0.43
▸ GAA P10253 2/20 0.43
▸ ALDH1A3 P47895 1/20 0.43
▸ MAPK1 P28482 1/20 0.43
▸ MEN1 O00255 1/20 0.43
▸ CYP1A2 P05177 1/20 0.42
▸ CYP2C9 P11712 1/20 0.42
▸ PKM P14618 1/20 0.42
▸ CYP2C19 P33261 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8619807 0.84 KMT2A (0.53) KMT2APTPN5PARP10ALDH1A1POLB
SCHEMBL30087591 0.84 PARP10 (0.56) KMT2APTPN5PARP10ALDH1A1POLB
SCHEMBL17420611 0.79 CA1 (0.50) ALDH1A1LMNAMAPK1
SCHEMBL17420587 0.79 PTPN5 (0.48) KMT2APTPN5PARP10ALDH1A1POLB
SCHEMBL13199203 0.78 GRB2 (0.57) KMT2AALDH1A1GRB2MEN1CYP1A2
SCHEMBL16579071 0.77 KMT2A (0.53) KMT2APTPN5PARP10ALDH1A1POLB
SCHEMBL17420441 0.77 TSHR (0.48) PTPN5GRB2LMNASMN1; SMN2
SCHEMBL17420410 0.77 ALDH1A1 (0.46) KMT2APTPN5PARP10ALDH1A1POLB
SCHEMBL17420711 0.77 ALDH1A1 (0.46) KMT2APTPN5PARP10ALDH1A1POLB
SCHEMBL1819106 0.77 GRB2 (0.48) ALDH1A1GRB2CYP2C19HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-111170991-B Antiproliferative compounds and methods of synthesis thereof 细胞基因公司 2023-10-31 — — CN disclosed
EP-3594211-B1 ANTIPROLIFERATIVE COMPOUNDS AND METHODS OF USE THEREOF CELGENE CORP (US) 2023-10-25 — — EP disclosed
US-20220387413-A1 ANTIPROLIFERATIVE COMPOUNDS AND METHODS OF USE THEREOF CELGENE CORP (US) 2022-12-08 — — US disclosed
US-11241423-B2 Antiproliferative compounds and methods of use thereof CELGENE CORPORATION (US) 2022-02-08 — — US disclosed
US-20200163948-A1 ANTIPROLIFERATIVE COMPOUNDS AND METHODS OF USE THEREOF CELGENE CORP (US) 2020-05-28 — — US disclosed
CN-111170991-A Antiproliferative compounds and methods of synthesis thereof 细胞基因公司 2020-05-19 — — CN disclosed
CN-106660991-B Antiproliferative compounds and methods of use thereof 细胞基因公司 2020-03-13 — — CN disclosed
EP-3166937-B1 ANTIPROLIFERATIVE COMPOUNDS AND METHODS OF USE THEREOF CELGENE CORP (US) 2019-09-04 — — EP disclosed
US-20180221361-A1 ANTIPROLIFERATIVE COMPOUNDS AND METHODS OF USE THEREOF CELGENE CORP (US) 2018-08-09 — — US disclosed
US-9968596-B2 Antiproliferative compounds and methods of use thereof CELGENE CORPORATION (US) 2018-05-15 — — US disclosed
US-20180021325-A1 ANTIPROLIFERATIVE COMPOUNDS AND METHODS OF USE THEREOF CELGENE CORP (US) 2018-01-25 — — US disclosed
US-9808451-B2 Antiproliferative compounds and methods of use thereof CELGENE CORPORATION (US) 2017-11-07 — — US disclosed
EP-3166937-A1 ANTIPROLIFERATIVE COMPOUNDS AND METHODS OF USE THEREOF Celgene Corporation (US) 2017-05-17 — — EP disclosed
US-20170007590-A1 ANTIPROLIFERATIVE COMPOUNDS AND METHODS OF USE THEREOF CELGENE CORP (US) 2017-01-12 — — US disclosed
US-9499514-B2 Antiproliferative compounds and methods of use thereof CELGENE CORPORATION (US) 2016-11-22 — — US disclosed
US-20160009683-A1 ANTIPROLIFERATIVE COMPOUNDS AND METHODS OF USE THEREOF CELGENE CORPORATION 2016-01-14 — — US disclosed
WO-2016007848-A1 ANTIPROLIFERATIVE COMPOUNDS AND METHODS OF USE THEREOF CELGENE CORPORATION (US) 2016-01-14 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220387413-A1 ANTIPROLIFERATIVE COMPOUNDS AND METHODS OF USE THEREOF MCL1, MKI67, BAX KMT2A 997/4885PTPN5 2463/4885PARP10 1333/4885
US-20170007590-A1 ANTIPROLIFERATIVE COMPOUNDS AND METHODS OF USE THEREOF MCL1, MKI67, BAX KMT2A 997/4885PTPN5 2463/4885PARP10 1333/4885
US-11241423-B2 Antiproliferative compounds and methods of use thereof MCL1, MKI67, BAX KMT2A 997/4885PTPN5 2463/4885PARP10 1333/4885
US-20200163948-A1 ANTIPROLIFERATIVE COMPOUNDS AND METHODS OF USE THEREOF MCL1, MKI67, BAX KMT2A 997/4885PTPN5 2463/4885PARP10 1333/4885
US-20160009683-A1 ANTIPROLIFERATIVE COMPOUNDS AND METHODS OF USE THEREOF MCL1, MKI67, BAX KMT2A 997/4885PTPN5 2463/4885PARP10 1333/4885
US-20180021325-A1 ANTIPROLIFERATIVE COMPOUNDS AND METHODS OF USE THEREOF MCL1, MKI67, BAX KMT2A 997/4885PTPN5 2463/4885PARP10 1333/4885
US-20180221361-A1 ANTIPROLIFERATIVE COMPOUNDS AND METHODS OF USE THEREOF MCL1, MKI67, BAX KMT2A 997/4885PTPN5 2463/4885PARP10 1333/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.